{"gao_id": "GAO-24-107359", "published": "2024-02-06T12:00:00Z", "released": "2024-02-05T07:00:00Z", "summary": "This testimony discusses our long-standing concerns about the Food and Drug Administration's oversight of the global pharmaceutical supply chain\u2014an issue on our High Risk List since 2009. More than 50% of drug manufacturers supplying the U.S. market are overseas. FDA inspections of manufacturers are critical for drug safety and effectiveness. But pandemic disruptions and staff shortages led to a backlog of foreign manufacturers needing inspection...", "title": "Drug Safety: FDA Has Faced Persistent Challenges Overseeing Foreign Drug Manufacturing", "topics": ["Social media", "pandemics", "High-risk series", "Drug safety", "Prescription drugs", "Health Care", "Supply chain management", "Foreign drug inspection", "Health care", "Drugs", "Manufacturing"], "type": "reports-testimonies", "url": "https://www.gao.gov/products/gao-24-107359", "versions": [{"title": "Full Report (9 pages)", "url": "https://www.gao.gov/assets/d24107359.pdf"}]}